Key result
Various therapeutic options for refractory angina pectoris have been shown in randomized trials to be reasonably effective in reducing symptoms, though further research is warranted.
Refractory angina is a growing clinical problem with significant impact on quality of life, for which various therapeutic options have shown reasonable effectiveness in reducing symptoms.
Refractory angina remains a growing clinical challenge in women; leaves open the role of novel neuromodulation approaches pending higher-level evidence.
Because of improvement in survival from coronary artery disease and increasing life expectancy of the population, chronicity and resistance to therapy have become growing problems confronting the cardiologist. Refractory angina pectoris is an entity based on clinical diagnosis, and it refers to recurrent and sustained chest pain more than 3 months duration caused by coronary insufficiency that is unamenable to conventional modalities of treatment, including drugs, percutaneous coronary interventions, or coronary bypass grafting. Individuals with this entity may have an impaired quality of life, with recurrent angina, poor general health and psychological distress impairing functional and productive sustenance. A multitude of therapeutic options exists for patients with refractory angina pectoris, and randomized trials have shown them to be reasonably effective in reducing symptoms, though further research is warranted.
No takes yet. Share an insight, caveat, or question.
Meenakshi et al. (2017) conducted a review in Refractory angina pectoris. Various therapeutic options was evaluated. Various therapeutic options for refractory angina pectoris have been shown in randomized trials to be reasonably effective in reducing symptoms, though further research is warranted.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: